Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STR04 in Amyotrophic Lateral Sclerosis
NCT06910384Phase 2Terminated
- Sponsor
- New England Cell Therapeutics
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of STR-04 in amyotrophic lateral sclerosis (ALS), sponsored by New England Cell Therapeutics. Started Aug 2025; status: terminated.
02
Drugs
STR-04
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06910384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06910384.